The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: A study based on 926 patients
Abstract
BACKGROUND: The current TNM staging system for patients with hepatocellular carcinoma (HCC) does not include liver function parameters and does not provide a precise prognosis for patients in different risk groups. The objectives of this study were to construct a new prognostic index for patients with hepatocellular carcinoma, the Chinese University Prognostic Index (CUPI), and to compare it with existing staging systems in terms of their ability to classify patients into different risk group. METHODS: From 1996 to 1998, 926 ethnic Chinese patients who were diagnosed with HCC (mainly hepatitis B‐associated) at a single institution were recruited prospectively into this study. A multivariate analysis on 19 patient characteristics was performed using a Cox regression model to identify independent prognostic factors. Weights were derived from the regression coefficients of various factors to construct the CUPI. Patients were classified according to different staging systems. Survival curves were plotted with the Kaplan–Meier method and were compared by using a log‐rank test. RESULTS: Both the TNM staging system and the Okuda staging system had prognostic significance, but the significance was lower for the Cancer of the Liver Italian Program (CLIP) prognostic score among the patients in the study population. The CUPI was constructed by adding the following factors into the TNM staging system: total bilirubin, ascites, alkaline phosphatase, α fetoprotein, and asymptomatic disease on presentation. The new CUPI characterized three risk groups with highly significant differences in survival during the whole period of follow‐up (P < 0.00001) and was more discriminant than the other systems. CONCLUSIONS: In the study population of patients with mainly hepatitis B‐associated HCC, the CUPI was more discriminant than the TNM staging system, the Okuda staging systems, or the CLIP prognostic score in classifying patients into different risk groups and was better at predicting survival. The CUPI needs to be validated by different cohorts of patients before it can be recommended for general use. Cancer 2002;94:1760–9. © 2002 American Cancer Society. DOI 10.1002/cncr.10384
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Okuda, K., Ohtsuki, T., Obata, H., Tomimatsu, M., Okazaki, N., Hasegawa, H., Nakajima, Y., & Ohnishi, K. (1985) · Cancer · doi:10.1002/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e · Cited by 1,931
A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients
(1998) · Hepatology · doi:10.1002/hep.510280322 · Cited by 1,238
TNM classification of malignant tumours
Cassoni, A. M. (1998) · Clinical Oncology · doi:10.1016/s0936-6555(98)80120-9 · Cited by 1,191
(2000) · Hepatology · doi:10.1053/he.2000.5628 · Cited by 521
A new prognostic classification for predicting survival in patients with hepatocellular carcinoma
Chevret, S., Trinchet, J.-C., Mathieu, D., Rached, A. A., Beaugrand, M., & Chastang, C. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80173-1 · Cited by 512
Increase in primary liver cancer in the UK, 1979–94
Taylor-Robinson, S. D., Foster, G. R., Arora, S., Hargreaves, S., & Thomas, H. C. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63789-0 · Cited by 506
Hepatocellular carcinoma in the United States: Prognostic features, treatment outcome, and survival
Stuart, K. E., Anand, A. J., & Jenkins, R. L. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960601)77:11<2217::aid-cncr6>3.0.co;2-m · Cited by 354
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“Among more comprehensive staging systems, five have been broadly tested, three European (the French classification [147], the Cancer of the Liver Italian Program (CLIP) classification [130], and the Barcelona-Clínic Liver Cancer (BCLC) staging system [148,149]) and two Asian (the Chinese University Prognostic Index (C…”
MethodLlovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Zhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,662
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
Hepatocellular carcinoma: clinical frontiers and perspectives
Bruix, J., Gores, G. J., & Mazzaferro, V. (2014) · Gut · doi:10.1136/gutjnl-2013-306627 · Cited by 1,364
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Clavien, P.-A., Lesurtel, M., Bossuyt, P. M., Gores, G. J., Langer, B., & Perrier, A. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70175-9 · Cited by 1,026
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Bruix, J., Raoul, J.-L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.014 · Cited by 822
Novel advancements in the management of hepatocellular carcinoma in 2008
Llovet, J. M., & Bruix, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.022 · Cited by 815
The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma
Llovet, J. M., Fuster, J., & Bruix, J. (2004) · Liver Transplantation · doi:10.1002/lt.20034 · Cited by 700
Yau, T., Tang, V. Y. F., Yao, T.-J., Fan, S.-T., Lo, C.-M., & Poon, R. T. P. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.032 · Cited by 698
Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort†
Marrero, J. A., Fontana, R. J., Barrat, A., Askari, F., Conjeevaram, H. S., Su, G. L., & Lok, A. S. (2005) · Hepatology · doi:10.1002/hep.20636 · Cited by 637
Biology and significance of alpha-fetoprotein in hepatocellular carcinoma
Galle, P. R., Foerster, F., Kudo, M., Chan, S. L., Llovet, J. M., Qin, S., Schelman, W. R., Chintharlapalli, S., Abada, P. B., Sherman, M., et al. (2019) · Liver International · doi:10.1111/liv.14223 · Cited by 597
Raoul, J.-L., Sangro, B., Forner, A., Mazzaferro, V., Piscaglia, F., Bolondi, L., & Lencioni, R. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.006 · Cited by 537
Updated treatment approach to hepatocellular carcinoma
Llovet, J. M. (2005) · Journal of Gastroenterology · doi:10.1007/s00535-005-1566-3 · Cited by 508
Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment
Piñero, F., Dirchwolf, M., & Pessôa, M. G. (2020) · Cells · doi:10.3390/cells9061370 · Cited by 498
Treatment of intermediate-stage hepatocellular carcinoma
Forner, A., Gilabert, M., Bruix, J., & Raoul, J.-L. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.122 · Cited by 466
Prospective validation of the Barcelona Clinic Liver Cancer staging system
Cillo, U., Vitale, A., Grigoletto, F., Farinati, F., Brolese, A., Zanus, G., Neri, D., Boccagni, P., Srsen, N., D'Amico, F., et al. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.12.015 · Cited by 425
Poon, D., Anderson, B. O., Chen, L.-T., Tanaka, K., Lau, W. Y., Van Cutsem, E., Singh, H., Chow, W. C., Ooi, L. L., Chow, P., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70241-4 · Cited by 410
Self-citationThomas, M. B., Jaffe, D., Choti, M. M., Belghiti, J., Curley, S., Fong, Y., Gores, G., Kerlan, R., Merle, P., O'Neil, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.7805 · Cited by 394
Liu, C.-Y., Chen, K.-F., & Chen, P.-J. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021535 · Cited by 391
Advanced Hepatocellular Carcinoma: Which Staging Systems Best Predict Prognosis?
Huitzil-Melendez, F.-D., Capanu, M., O'Reilly, E. M., Duffy, A., Gansukh, B., Saltz, L. L., & Abou-Alfa, G. K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9895 · Cited by 335
Minagawa, M., Ikai, I., Matsuyama, Y., Yamaoka, Y., & Makuuchi, M. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000254368.65878.da · Cited by 330
MicroRNA involvement in hepatocellular carcinoma
Gramantieri, L., Fornari, F., Callegari, E., Sabbioni, S., Lanza, G., Croce, C. M., Bolondi, L., & Negrini, M. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00533.x · Cited by 304
Cancer and liver cirrhosis: implications on prognosis and management
Pinter, M., Trauner, M., Peck-Radosavljevic, M., & Sieghart, W. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000042 · Cited by 295
Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients
Tateishi, R., Yoshida, H., Shiina, S., Imamura, H., Hasegawa, K., Teratani, T., Obi, S., Sato, S., Koike, Y., Fujishima, T., et al. (2005) · Gut · doi:10.1136/gut.2003.035055 · Cited by 273
Comparison of hepatocellular carcinoma in Eastern versus Western populations
Choo, S. P., Tan, W. L., Goh, B. K. P., Tai, W. M., & Zhu, A. X. (2016) · Cancer · doi:10.1002/cncr.30237 · Cited by 264
Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems
Liu, P.-H., Hsu, C.-Y., Hsia, C.-Y., Lee, Y.-H., Su, C.-W., Huang, Y.-H., Lee, F.-Y., Lin, H.-C., & Huo, T.-I. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.029 · Cited by 263
Metadata
- Authors
- Leung, T. W. T., Tang, A. M. Y., Zee, B., Lau, W. Y., Lai, P. B. S., Leung, K. L., Lau, J. T. F., Yu, S. C. H., & Johnson, P. J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2002-03-15
- Volume
- 94
- Issue
- 6
- Pages
- 1760-1769
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1993128964
- Cited by
- 583
- References
- 14
- FWCI
- 10.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.